Because insulin resistance plays a prominent part in the development of Type II diabetes [1, 2] , therapeutic interventions to improve insulin action are likely to be of considerable benefit in the management of the condition. The thiazolidinediones (or glitazones) are a new class of orally active drugs that reduce insulin resistance [3] and hence increase glucose uptake in skeletal muscle and adipose tissue, as well as decrease hepatic glucose production. These effects are thought to be mediated through interactions of these drugs with the gamma subtype of the peroxisome proliferator-activated receptor gamma (PPARg) [4, 5] .
differences in the side chains result in differences in bioavailability, metabolism and antihyperglycaemic action [5] . Rosiglitazone is the most potent agent in the class, being 100 times more potent than troglitazone in terms of its activation of PPARg [4] . A previous dose-ranging study has adequately described the safety and efficacy of rosiglitazone at the lower end of the dose-response curve [6] . This study was designed to compare the effects of rosiglitazone given at a dose range of 2, 4 and 6 mg twice daily versus placebo in individuals with Type II diabetes and to investigate the effects of rosiglitazone on postprandial glucose excursions.
Subjects and methods
Subjects. Patients were eligible for the study if they were 40 to 80 years of age and had Type II (non-insulin-dependent) diabetes mellitus (defined by the National Diabetes Data Group [7] ), a fasting plasma glucose (FPG) concentration 7.8 mmol/l or more and 16.7 mmol/l or more and evidence of residual insulin secretory capacity as determined by a fasting C-peptide concentration 0.27 nmol/l or more (Table 1) . Patients with clinically important renal (serum creatinine > 160 mmol/l) or hepatic disease (ALT, AST, total bilirubin or alkaline phosphatase > 2.5 times upper limit of the normal range), symptomatic angina pectoris or cardiac insufficiency (New York Heart Association functional class III or IV) or haematologic abnormalities were excluded from the study. Patients who required insulin therapy were not eligible for the study.
All patients were withdrawn from previous antidiabetic medication for 2 weeks before entrance into the study. During the 3 months before the study, 166 (58.5 %) of the patients had been treated with a single antihyperglycaemic agent. Approximately 25 % were managed with diet alone and the remainder of the patients received therapy with more than one drug.
Study protocol. This multicentre, randomised, double-masked, placebo-controlled trial was conducted at 35 sites throughout the United States. All patients received placebo twice daily by mouth for 2 weeks during the single-masked run-in period. Patients were then randomly assigned to 8 weeks of doublemasked treatment with placebo or with rosiglitazone at doses of 2 mg, 4 mg or 6 mg given twice daily. The study was conducted in accordance with the Declaration of Helsinki, Title 21 of the US Code of Federal Regulations and Good Clinical Practice guidelines. All study subjects gave written, informed consent before study enrolment. Statistical analysis. All statistical analysis was done using SAS for Windows (version 6.1). An analysis of covariance (AN-COVA) was used for the assessment of differences in continuous variables between the treatment groups. The results obtained using the full model including treatment-by-baseline and treatment-by-region interaction terms were compared with those obtained by a one-way analysis of variance (ANO-VA) model; the conclusions were the same for both models.
Difference from baseline was assessed by paired Student's t test. The Williams procedure was used to determine the minimum effective rosiglitazone dose compared with placebo. An intention-to-treat analysis with the last observation carried forward was used. Data are expressed as means ± SD; p values of 0.05 or less were considered to be statistically significant.
Results
Of the 529 patients screened, 303 were found to be eligible and were randomly assigned to double-masked treatment. Baseline demographic and metabolic characteristics were similar in the four treatment groups (Table 1) .
Glycaemic control. Rosiglitazone significantly reduced mean fasting plasma glucose (FPG) concentration compared with both baseline and placebo (all p < 0.0001). Improved glycaemic control was evident from the first visit following initiation of therapy. After 8 weeks of placebo treatment, the mean FPG increased significantly from a baseline value of 12.7 ± 3.5 mmol/l to 13.8 ± 3.9 mmol/l (p = 0.0004). Rosiglitazone therapy significantly decreased FPG (p < 0.0001) in the 2-mg twice-daily (12.7 ± 3.9 to 10.7 ± 3.6 mmol/l), 4-mg twice-daily (12.8 ± 3.7 to 10.4 ± 3.6 mmol/l) and 6-mg twice-daily (12.6 ± 3.3 to 10.0 ± 3.5 mmol/l) groups (Fig. 1 , Table 2 ). The rate of decline in mean FPG was greatest during the first 4 weeks of treatment in all rosiglitazone treatment groups. Additional decreases in FPG were observed between weeks 4 and 8.
Fructosamine. After 8 weeks of treatment, fructosamine concentrations had decreased significantly in the rosiglitazone 4 and 6-mg twice-daily treatment groups relative to baseline (p < 0.0001 and p = 0.0033, respectively) and in all rosiglitazone treatment groups compared with placebo (p < 0.0001) (decreases of 3.3 ± 61.8, 27.2 ± 46.36 and 19.9 ± 56.89 mmol/l in the rosiglitazone 2-, 4-and 6-mg twice-daily groups compared with an increase of 39.0 ± 66.91 mmol/l in the placebo group).
Haemoglobin A 1c . In the rosiglitazone 2-mg twicedaily treatment group and in the placebo group, 10.4 ± 3.56 10.0 ± 3.49 a n = 74 at 4 weeks and 75 at 8 weeks. bd = twice daily, RSG = rosiglitazone mean HbA 1 c values increased significantly (p £ 0.0025 and p < 0.0001, respectively) from baseline to week 8 (from 0.087 ± 0.014 to 0.091 ± 0.018 and from 0.087 ± 0.016 to 0.097 ± 0.020, respectively). In contrast, no increase occurred in patients treated with rosiglitazone at 4 and 6 mg twice daily. For all doses of rosiglitazone, these changes differed significantly from the change in the placebo group (p < 0.0001 for 4 mg and 6 mg twice daily vs placebo; p = 0.0029 for 2 mg twice daily vs placebo).
Insulin and C peptide. Insulin concentrations decreased significantly from baseline in rosiglitazonetreated patients (p < 0.05) but not in placebo-treated patients (Table 3) . Rosiglitazone 6 mg twice daily significantly reduced plasma insulin concentrations compared with placebo (p < 0.05). Mean C peptide concentrations decreased significantly from baseline in all of the rosiglitazone treatment groups (all p £ 0.0002), although there was no significant difference from placebo.
Lipids. Rosiglitazone significantly reduced mean NEFA concentrations compared with baseline and placebo (p < 0.0001) ( Table 4) . Mean increases in total cholesterol and LDL cholesterol for each rosiglitazone dose were significantly greater than those in the placebo group (p < 0.0001 and p < 0.0004, respectively). There were no mean changes in HDL compared with placebo and there were no clinically meaningful changes in mean total cholesterol:HDL or mean LDL:HDL ratios. Rosiglitazone did not affect mean triglyceride concentrations.
Postprandial analysis. The area under time-concentration curve (AUC) of blood glucose was determined in approximately 30 % of the study patients (18, 25, 24 and 22 patients in the placebo and the 2-, 4-and 6-mg rosiglitazone twice-daily groups, respectively). The numbers of patients in each group are not exactly equal because some patients were missing baseline or end-point data. Significant reductions in postprandial glucose (PPG) AUCs were observed in all rosiglitazone treatment groups compared with both placebo and baseline (Fig. 2) . Peak PPG concentrations were generally observed 90 min after a meal. Mean peak PPG concentrations at week 8 were 20 mmol/l in the placebo-treated group and 14 mmol/l for rosiglitazone-treated patients. The change in PPG from week 0 to week 8 in the placebo and the rosiglitazone 4-mg twice-daily groups was examined by evaluating the AUC of PPG normalised to the time zero (fasting) value (Fig. 3) . The area under the PPG curve was calculated from the time of the meal to 180 min after the meal. In placebo-treated patients, the area under the PPG curve did not change between baseline and week 8, whereas rosiglitazone 4-mg twice daily reduced area under the PPG curve by 19 % (95 % confidence interval [CI], ±36.6 % to ±2.0 %) from baseline to week 8. No change in postprandial AUC insulin or AUC triglycerides occurred in rosiglitazone-treated patients between week 0 and week 8.
Safety and tolerability. More rosiglitazone patients (87 %) than placebo patients (76 %) completed the study. Approximately 9.3 % of patients in the placebo group and 5.1 %, 4.2 % and 3.8 % of patients in the 2-, 4-and 6-mg rosiglitazone twice-daily treatment groups, respectively, withdrew from the study because of an adverse event. Less than 2 % of rosiglitazone patients withdrew for lack of efficacy compared with 5 % of placebo patients. The proportion of patients with at least one adverse event was similar in the four groups: 56.4 %, 54.9 % and 49.4 % in the rosiglitazone 2-, 4-and 6-mg twice-daily treatment groups, respectively, compared with 49.3 % in the placebo group. There were no notable changes in liver function tests in rosiglitazone-treated or placebo-treated patients. The week-8 mean AST values for the placebo and rosiglitazone 2-, 4-and 6-mg groups were 18.7 ± 8.36, 19.1 ± 8.23, 17.5 ± 9.96 and 15.6 ± 5.05 U/l, respectively; the week-8 mean ALT values were 23.4 ± 12.28, 21.4 ± 10.62, 20.6 ± 15.85 and 16.2 ± 6.04 U/l, respectively. One patient in the 6-mg twice-daily group withdrew because of oedema. Seven patients in the 6-mg twice-daily group, three in the 4-mg twice-daily group and one in the 2-mg twice-daily group had decreases in haemoglobin or haematocrit that were potentially clinically meaningful, but no patient withdrew from the study because of these adverse events or laboratory abnormalities. Mean changes from baseline in haemoglobin levels were ±0.2 ± 0.37, ±0.5 ± 0.38 and ±0.6 ± 0.45 mmol/l for the 2-mg, 4-mg and 6-mg rosiglitazone treatment groups, respectively, and mean changes from baseline in haematocrit levels were ±1.2 % ± 1.91 %, ±2.5 % ± 1.88 % and ±3.0 % ± 2.29 %, respectively. Small increases in body weight were noted in the rosiglitazone 4-and 6-mg twice-daily groups (0.7 ± 2.34 kg and 1.5 ± 2.45 kg, respectively). 
Discussion
This dose-ranging study clearly shows that rosiglitazone given as monotherapy in doses of 2, 4 and 6 mg twice daily reduces fasting and postprandial glucose concentrations. Reductions in fasting plasma glucose were observed in rosiglitazone-treated patients at the first office visit after the initiation of therapy, after only 4 weeks of treatment; additional improvement in glycaemic control was seen in rosiglitazonetreated patients after 8 weeks. Consistent with the short duration of treatment, reductions in fasting and postprandial glucose concentrations were best reflected in statistically significant differences in fructosamine between the placebo and rosiglitazone groups. Significant effects on HbA 1 c are not expected in an 8-week study. Despite the relatively short duration of this study, some reduction in the HbA 1 c values was, however, observed. The effects of the 4-mg twice-daily dose were similar to those of the 6-mg twice-daily dose, suggesting that the top of the doseresponse curve had been attained. Treatment with rosiglitazone at all doses significantly reduced fasting plasma glucose concentrations and postprandial glucose peak concentrations and excursions, which appears to be primarily reflective of glucose disposition. The reduction in postprandial glucose with rosiglitazone is noteworthy because high postprandial glucose concentrations are associated with an increased risk of coronary artery disease [9±11], microvascular complications [12, 13] and a 1.5-fold to threefold increase in the risk of sudden cardiac death [14] . Improved glycaemic control occurred in rosiglitazone-treated patients without an accompanying increase in fasting or postprandial insulin concentrations. This finding is consistent with the concept that rosiglitazone improves peripheral insulin sensitivity and subsequently improves glucose uptake by skeletal muscle [15] . It has been previously shown that 80±90 % of insulin-stimulated glucose uptake occurs in skeletal muscle [15] .
Rosiglitazone reduced NEFA concentrations. Raised NEFA concentrations are associated with the development of hypertension [16] . They are also known to increase insulin resistance in skeletal muscle and inhibit beta-cell function [17±20].
Total cholesterol and LDL cholesterol concentrations were increased by 6 mg twice-daily rosiglitazone; the total cholesterol/HDL cholesterol ratio, considered a strong marker of cardiovascular risk, was, however, unchanged. These lipid changes have also been seen with other thiazolidinedione therapy [21] . Serum triglyceride concentrations, both fasting and postprandial, were unchanged by rosiglitazone treatment. Rosiglitazone was well tolerated. The overall frequency of adverse events was similar between the rosiglitazone and placebo treatment groups. No rosiglitazone patient withdrew from the study because of abnormal laboratory test values.
Rosiglitazone improved fasting and postprandial glucose concentrations compared with baseline and with placebo in patients with Type II diabetes. Doseresponse data reported here suggest that rosiglitazone will be useful at doses of 4 mg to 8 mg a day. Rosiglitazone reduced insulin and NEFA in addition to lowering glucose concentrations. The actions of rosiglitazone in this study are consistent with its activity as an insulin-sensitising agent and support its benefits in the treatment of Type II diabetes.
